David Bautz
Analyst-Equity chez Zacks Investment Research, Inc. (Small Cap Research)
Profil
Dr. David Bautz is a Senior Biotechnology Analyst at Zacks Investment Research, Inc. He joined the firm in February 2014.
Dr. Bautz worked for two years as a Research Associate at Human Genome Sciences, Inc., a biotechnology company that was eventually acquired by GlaxoSmithKline.
He obtained his PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill in 2008.
His dissertation research focused on the characterization of autoantibodies in patients suffering from an orphan autoimmune disease.
He obtained his BS and MS degrees in Biochemistry from Virginia Tech.
Postes actifs de David Bautz
| Sociétés | Poste | Début |
|---|---|---|
| Zacks Investment Research, Inc. (Small Cap Research) | Analyst-Equity | 01/02/2014 |
Formation de David Bautz
| The University of North Carolina at Chapel Hill | Doctorate Degree |
| Virginia Polytechnic Institute & State University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
| Zacks Investment Research, Inc. (Small Cap Research) | Finance |
